<DOC>
	<DOCNO>NCT00389285</DOCNO>
	<brief_summary>The purpose study evaluate whether recombinant IL-21 use combination sorafenib safe patient metastatic renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Study Recombinant Interleukin 21 Combination With Sorafenib Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This Phase 1/2 open-label dose-escalation study rIL-21 give combination sorafenib patient metastatic RCC . The Phase 1 part study estimate maximum tolerate dose rIL-21 give 1 treatment course ( consist two 5-day cycle rIL-21 ) combination standard dose sorafenib administer 6-week treatment course . Increasing dose rIL-21 study sequentially different group patient . The Phase 2 part study evaluate safety preliminary antitumor activity rIL-21 dose recommend Phase 1 combination sorafenib . Patients evaluate safety course study . Disease evaluation ( tumor restaging ) perform last week 6-week treatment course . Patients stable disease good evaluation may go receive additional treatment course . Patients may study 2 7 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis RCC predominantly clear cell histology Either prior treatment maximum 2 prior treatment regimens metastatic RCC include 1 treatment regimen target vascular endothelial growth factor ( VEGF ) pathway ( Phase 1 ) At least 1 2 prior systemic therapy metastatic RCC include 1 therapy target VEGF pathway ( Phase 2 ) Disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST ) ( Phase 2 ) Presence acute infection significant systemic illness Central nervous system involvement malignancy History cancer within 5 year Previously receive rIL21 sorafenib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Carcinoma , renal cell</keyword>
	<keyword>interleukin-21</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>